link
Bookmarks
Subependymal Giant Cell Astrocytoma
Luke L. Linscott, MDAnne G. Osborn, MD, FACRJohn H. Rees, MD
To access 4,300 diagnoses written by the world's leading experts in radiology.Try it free - 15 days
0
5
0
3

KEY FACTS

  • Terminology

    • Imaging

      • Top Differential Diagnoses

        • Pathology

          • Clinical Issues

            • Diagnostic Checklist

              TERMINOLOGY

              • Abbreviations

                • Subependymal giant cell astrocytoma (SGCA, SEGA)
              • Synonyms

                • Intraventricular astrocytoma of tuberous sclerosis complex (TSC)
              • Definitions

                • Benign, slow-growing glioneuronal tumor usually arising adjacent to foramen of Monro in TSC

              IMAGING

              • General Features

                • CT Findings

                  • MR Findings

                    • Ultrasonographic Findings

                      • Angiographic Findings

                        • Imaging Recommendations

                          DIFFERENTIAL DIAGNOSIS

                            PATHOLOGY

                            • General Features

                              • Staging, Grading, & Classification

                                • Gross Pathologic & Surgical Features

                                  • Microscopic Features

                                    CLINICAL ISSUES

                                    • Presentation

                                      • Demographics

                                        • Natural History & Prognosis

                                          • Treatment

                                            DIAGNOSTIC CHECKLIST

                                            • Consider

                                              • Image Interpretation Pearls

                                                Selected References

                                                1. Trelinska J et al: Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatr Blood Cancer. 64(6), 2017
                                                2. French JA et al: Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 388(10056):2153-63, 2016
                                                3. Beaumont TL et al: Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. J Neurosurg Pediatr. 1-4, 2015
                                                4. Kwiatkowski DJ et al: Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur J Hum Genet. 23(12):1665-72, 2015
                                                5. Cardamone M et al: Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 164(5):1195-200, 2014
                                                6. Franz DN et al: Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15(13):1513-20, 2014
                                                7. Harter DH et al: A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr. 13(1):21-8, 2014
                                                8. Kotulska K et al: Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 50(4):307-12, 2014
                                                9. Ouyang T et al: Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst. 30(4):561-70, 2014
                                                10. Rovira À et al: Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. J Neurooncol. 118(2):205-23, 2014
                                                11. Krueger DA et al: Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 80(6):574-80, 2013
                                                12. Roth J et al: Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 49(6):439-44, 2013
                                                13. Buccoliero AM et al: Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 29(1):25-30, 2009
                                                14. Ess KC et al: Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology. 64(8):1446-9, 2005
                                                15. You H et al: Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol. 74(1):1-8, 2005
                                                16. Chan JA et al: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 63(12):1236-42, 2004
                                                17. Cuccia V et al: Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 19(4):232-43, 2003
                                                18. Koeller KK et al: From the archives of the AFIP. Cerebral intraventricular neoplasms: radiologic-pathologic correlation. Radiographics. 22(6):1473-505, 2002
                                                19. Medhkour A et al: Neonatal subependymal giant cell astrocytoma. Pediatr Neurosurg. 36(5):271-4, 2002
                                                20. Nishio S et al: Tumours around the foramen of Monro: clinical and neuroimaging features and their differential diagnosis. J Clin Neurosci. 9(2):137-41, 2002
                                                Related Anatomy
                                                Loading...
                                                Related Differential Diagnoses
                                                Loading...
                                                References
                                                Tables

                                                Tables

                                                KEY FACTS

                                                • Terminology

                                                  • Imaging

                                                    • Top Differential Diagnoses

                                                      • Pathology

                                                        • Clinical Issues

                                                          • Diagnostic Checklist

                                                            TERMINOLOGY

                                                            • Abbreviations

                                                              • Subependymal giant cell astrocytoma (SGCA, SEGA)
                                                            • Synonyms

                                                              • Intraventricular astrocytoma of tuberous sclerosis complex (TSC)
                                                            • Definitions

                                                              • Benign, slow-growing glioneuronal tumor usually arising adjacent to foramen of Monro in TSC

                                                            IMAGING

                                                            • General Features

                                                              • CT Findings

                                                                • MR Findings

                                                                  • Ultrasonographic Findings

                                                                    • Angiographic Findings

                                                                      • Imaging Recommendations

                                                                        DIFFERENTIAL DIAGNOSIS

                                                                          PATHOLOGY

                                                                          • General Features

                                                                            • Staging, Grading, & Classification

                                                                              • Gross Pathologic & Surgical Features

                                                                                • Microscopic Features

                                                                                  CLINICAL ISSUES

                                                                                  • Presentation

                                                                                    • Demographics

                                                                                      • Natural History & Prognosis

                                                                                        • Treatment

                                                                                          DIAGNOSTIC CHECKLIST

                                                                                          • Consider

                                                                                            • Image Interpretation Pearls

                                                                                              Selected References

                                                                                              1. Trelinska J et al: Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatr Blood Cancer. 64(6), 2017
                                                                                              2. French JA et al: Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 388(10056):2153-63, 2016
                                                                                              3. Beaumont TL et al: Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. J Neurosurg Pediatr. 1-4, 2015
                                                                                              4. Kwiatkowski DJ et al: Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur J Hum Genet. 23(12):1665-72, 2015
                                                                                              5. Cardamone M et al: Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 164(5):1195-200, 2014
                                                                                              6. Franz DN et al: Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15(13):1513-20, 2014
                                                                                              7. Harter DH et al: A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr. 13(1):21-8, 2014
                                                                                              8. Kotulska K et al: Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 50(4):307-12, 2014
                                                                                              9. Ouyang T et al: Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst. 30(4):561-70, 2014
                                                                                              10. Rovira À et al: Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. J Neurooncol. 118(2):205-23, 2014
                                                                                              11. Krueger DA et al: Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 80(6):574-80, 2013
                                                                                              12. Roth J et al: Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 49(6):439-44, 2013
                                                                                              13. Buccoliero AM et al: Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 29(1):25-30, 2009
                                                                                              14. Ess KC et al: Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology. 64(8):1446-9, 2005
                                                                                              15. You H et al: Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol. 74(1):1-8, 2005
                                                                                              16. Chan JA et al: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 63(12):1236-42, 2004
                                                                                              17. Cuccia V et al: Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 19(4):232-43, 2003
                                                                                              18. Koeller KK et al: From the archives of the AFIP. Cerebral intraventricular neoplasms: radiologic-pathologic correlation. Radiographics. 22(6):1473-505, 2002
                                                                                              19. Medhkour A et al: Neonatal subependymal giant cell astrocytoma. Pediatr Neurosurg. 36(5):271-4, 2002
                                                                                              20. Nishio S et al: Tumours around the foramen of Monro: clinical and neuroimaging features and their differential diagnosis. J Clin Neurosci. 9(2):137-41, 2002